Skip to main content
Logo GMV

Main navigation

  • Sectors
    • Icono espacio
      Space
    • Icono Aeronáutica
      Aeronautics
    • Icono Defensa y Seguridad
      Defense and Security
    • Icono Sistemas Inteligentes de Transporte
      Intelligent Transportation Systems
    • Icono Automoción
      Automotive
    • Icono Ciberseguridad
      Cybersecurity
    • Icono Servicios públicos Digitales
      Digital Public Services
    • Icono Sanidad
      Healthcare
    • Icono Industria
      Industry
    • Icono Financiero
      Financial
    • Icono Industria
      Services
    • All Sectors

    Highlight

    European Conference on Space Debris
    Our present and future: A tour through the European Conference on Space Debris
  • Talent
  • About GMV
    • Get to Know the Company
    • History
    • Management Team
    • Certifications
    • Corporate Social Responsibility
  • Communication
    • News
    • Events
    • Blog
    • Magazine GMV News
    • Press Room
    • Media library
    • Latest from GMV

Secondary navigation

  • Products A-Z
  • GMV Global
    • Global (en)
    • Spain and LATAM (es - ca - en)
    • Germany (de - en)
    • Portugal (pt - en)
    • Poland (pl - en)
    • All branches and all GMV sites
  • Home
  • Communication
  • News
Back
New search
Date
  • Healthcare

GMV applies Big Data to the investigation of hematologic malignancies

25/01/2018
  • Print
Share
GMV applies Big Data to the investigation of hematologic malignancies
GMV, the only technology firm in the HARMONY Alliance, has presented the Big Data platform for recording the data of blood-cancer patients from Germany, Spain, France, England and Italy at the 2nd General Assembly held in Berlin. 

The Harmony Alliance is an unprecedented Big-Data-driven initiative in the fight against blood cancers. Its partners include 51 key organizations from all the following fields: clinical, academic, patients, healthcare technology assessment, legislation, economic, ethical and pharmaceutical.

In the first phase Harmony aims to set up an ethical and legal framework on the use of medical data, analyzing the first platform data and defining sets of standard results.

Inmaculada Pérez Garro

In the words of Inmaculada Pérez Garro, GMV’s Head of Big Data Healthcare Projects, during this first stage of the project “We have tackled the challenge of harmonizing patient-protection data legislation under a single framework to be able to work with a common model adhering to the FAIR (findable, accessible, interoperable y reusable) data exchange principles”.

As from today “We can now go on to make further headway in the recording, processing and harmonization of huge volumes of data that will later help us to obtain evidence on the behavior of blood cancers like acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin lymphoma, myelodysplastic syndromes and pediatric hematologic diseases”.

One non-technological factor that also called for a big effort was the definition and design of procedures allowing users to ask the platform questions and obtain evidence. To this end, as explained by Pérez Garro “We have liaised with various specialists among the partners making up the public-private HARMONY consortium: engineers, members of ethical committees, legal specialists, clinicians, etc, to agree on the best solutions from the various standpoints”.

Applying advanced analytical techniques to the huge volumes of data uploaded into the Big Data platform, GMV will be furnishing information that enables specialists to analyze the behavior and evolution of these diseases in different habitats, characterize them more specifically, identifying molecular, genetic and clinical markers that flag up the population affected by a given disease. This will contribute towards “The development of new therapies capable of personalizing treatment and providing benefits for patients such as avoiding exposure to unnecessary toxicity levels” argued the executive. 

  • Print
Share

Related

Premios IA con Impacto Social
  • Healthcare
The GMV-led Tartaglia project wins the "AI with Social Impact Prize".
np_011_ia-lung-scan.jpg
  • Healthcare
Innovative artificial intelligence-based simulator for the diagnosis of interstitial lung diseases
np_011_ia-lung-scan.jpg
  • Healthcare
GMV designs a groundbreaking artificial intelligence-based simulator for diagnosing interstitial lung diseases

Contact

Europaplatz 2
64293 Darmstadt | Deutschland
Tel. +49 6151 3972 970
Fax. +49 6151 8609 415

Zeppelinstraße, 16
82205 Gilching | Deutschland
Tel. +49 (0) 8105 77670 150
Fax. +49 (0) 8105 77670 298

Contact menu

  • Contact
  • GMV around the world

Blog

  • Blog

Sectors

Sectors menu

  • Space
  • Aeronautics
  • Defense and Security
  • Intelligent Transportation Systems
  • Automotive
  • Cybersecurity
  • Digital Public Services
  • Healthcare
  • Industry
  • Financial
  • Services
  • Talent
  • About GMV
  • Shortcut to
    • Press Room
    • News
    • Events
    • Blog
    • Products A-Z
© 2025, GMV Innovating Solutions S.L.

Footer menu

  • Contact
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Impressum

Footer Info

  • Commitment to the Environment
  • Financial Information